Pathophysiology, diagnosis and treatment of intermittent claudication in patients with lumbar canal stenosis

Table 2 Effect of lipo-prostaglandin E₁ on patients with neurogenic intermittent claudication in lumbar canal stenosis

Author	Year	Drag	Dose	Period	Effective rate to NIC
Takakura[66]	1986	PGE1	40-60 μg/d	14-28 consecutive days	79.5% (39/49 cases)
Miura et al[67]	1992	Lipo-PGE1	10 μg/d	10 d	57.1% (8/14 cases)
Toribatake et al[68]	1993	Lipo-PGE1	10 μg/d	10 consecutive days	75.0% (12/16 cases)
Kurihara et al[69]	1996	Limaprost	3 μg/d	42 consecutive days	27.3% (21/77 cases)
			15 μg/d		47.8% (33/69 cases)
Murakami et al[70]	1997	Lipo-PGE1	10 μg/d	10 consecutive days	77.5% (31/40 cases)
			5 μg/d		87.0% (40/46 cases)
Ono et al[71]	1997	Lipo-PGE1	10 μg/d	14 consecutive days	71.1% (27/38 cases)
			20 μg/d		76.5% (26/34 cases)
Miura et al[72]	1997	PGE1	120 μg/d	14 consecutive days	33.0% (5/12 cases)
Uratuji et al[73]	2003	Limaprost	15 μg/d	42 consecutive days	59.3% (54/91 cases)
Harrison et al[74]	2007	Limaprost	15 μg/d	42 consecutive days	50.7% (74/146 cases)
Nakanishi et al[75]	2008	PGE1	60 μg/d	14 consecutive days	71.4% (45/63 cases)

Reproduced with permission from Kobayashi et al[81]. NIC: Neurogenic intermittent claudication; PGE₁: Prostaglandin E₁.